Fig. 2
MTL-CEBPA increases liver expression of CEBPA in DEN-induced HCC Wistar rats. a MTL-CEBPA showed a significant increase in CEBPA mRNA: **, p < 0.001. Albumin showed a tendency to increase after MTL-CEBPA treatment, however this was not statistically significant (p = 0.1769). Tumor nodule size and liver function tests were assessed in the DEN-induced cirrhotic HCC animals. b Liver tumor nodule size was measured from the biopsies across the pre-treatment control and two treatment groups. The average tumor size in the DEN only group (pre-treatment) was 193 ( ± 63) mm3. Over the 12-day course of the study period, the tumor size of animals treated with NOV340/FLUC at time of termination increased to 2204 ( ± 1031) mm3. All animals treated with MTL-CEBPA showed a slower rate of increase with an average volume of 401 ( ± 181)mm3 (p = 0.107 vs. NOV340/FLUC control). c Liver function parameters were measured for AST, ALT, albumin, and bilirubin. All showed a 30–50% decrease over the short study period. Ammonia decreased significantly despite the small group size. (*, p < 0.02)
